Genakumab not checked
Changchun GeneScience Pharmaceutical Co., Ltd. · GenSci048
FollowEvery change as it happens, and a Monday email
Trials
3 active
9 in total
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first);…”In the company’s words, NCT06189495 on ClinicalTrials.gov
- Tested for
- Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD), Uveitis, Endometriosis-related Pain
- Main trialPhase 2
- “This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)”In the company’s words, NCT06189495 on ClinicalTrials.gov
- Other names
- GenSci048
Other drugs for Uveitis
- ApremilastAmgen · Phase 3
- BaricitinibEli Lilly · Phase 3
- Brepocitinib QDPriovant Therapeutics, Inc. · Phase 3
- Hemay005Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 3
- FXS5626Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 2
- TulisokibartMerck & Co. · Phase 2
Coming up2
- 14 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 15 May 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Mar 2026 | A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease | |
| Phase 2Recruiting | 14 Dec 2027 | A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis. | |
| Phase 2Recruiting | 15 May 2028 | A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain | |
| Phase 3Completed | 3 Apr 2024 | Safety & Efffficacy of Genakumab in Patients With Frequent Flares | |
| Phase 2Completed | 19 Jan 2024 | A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) | |
| Phase 2Completed | 28 Feb 2024 | Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare | |
| Phase 1/2Completed | 9 Jun 2022 | Clinical Study of Genakumab for Injection in Patients With Acute Gout | |
| Phase 1Completed | 30 Nov 2023 | Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults | |
| Phase 1Completed | 29 Nov 2024 | A Bioequivalence Study of Two Different Dosage Form of Genakumab |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026